This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Researchers at the University of Sydney have developed experimental nose drops that enhance learning and memory in aged mice while also preventing memory loss in a mouse model of Alzheimer's disease. The treatment uses mRNA technology similar to that developed for use in COVID-19 vaccines.
The research, from the laboratory of Professor Greg Neely at the Charles Perkins Center, will lead to a new way to treat diseases of the brain, allowing for the development of medicines that target major neurological diseases, including neurodegeneration, stroke, traumatic brain injury and rare genetic and developmental diseases.
"If we can proceed quickly to clinical trials in humans, this approach could represent a world-first noninvasive delivery system to treat Alzheimer's that bypasses the blood-brain barrier," Neely said.
The study was inspired by the science fiction short story "Flowers for Algernon" written by Daniel Keyes, where scientists increase intelligence in lab mice and humans to better understand the limitations of human intelligence.
The findings show that delivering messenger RNA (mRNA) packaged in lipid nanoparticles (LNPs) can turn the nose into a drug factory, producing medically active proteins that can enter the brain and increase cognitive ability.
"In aged mice, we saw learning and memory significantly increased, returning animal cognition to its youthful prime," Neely said.
"What's exciting is that this was achieved with a simple noninvasive nasal delivery system that builds on the same underlying mRNA-LNP technology platform many people became familiar with during the COVID-19 pandemic."
Source link







